
ChatGPTãç æŽèŠçŽèªåäœæããããã«ãã-ç æŽèŠçŽå®å šèªååã«æ³ããã¯ãç ãã¬å€ãéãã-ããŒããŒãã§äžåå ¥åãªããã¯ãªãã¯ã®ã¿ã§ã¬ããŒãäœæããŠã¿ãã
ãã®èšäºã¯ããããæ¹ã«ãå§ã
ã»ã¬ããŒããèªåã§äœæããŠéãã§ã¿ãã
ã»äžæåãããŒããŒãã§æã¡ãããªã
ãå§ãã§ãªã
ã»æ©æ¢° (AI) ãªããã«ä»»ããããªã
ã»é«å質ãªã¬ããŒããäœæãããã
0. ã¯ããã«
0.1 æ¬èšäºã«ã€ããŠ
ChatGPTã¯ãèŠçŽããã¢ã€ãã¢åºãããªã©ã¯åŸæã§ãããèå¯ãã¯èŠæãšèšãããŠããŸããååã®èšäºãäœã£ãŠä»¥æ¥, ããã³ããæ¬¡ç¬¬ã§æå€ãšãèå¯ãæç« ããããã®ã§ã¯?ãšåžæãèŠããŠããŸããã
éå»3床ã«ãããèšäºãæžããŠããŸãããæåæ°ã2äžæåãè¶
ã, äœãèšãããã®ãåãããªããŸãšãŸãã®ãªãæç« ãšãªã£ãŠããŸããŸãããä»å, äœåãªè§£èª¬ã¯ããèœãšã, æäœæ³ãmainã«ãŸãšãããç·éç·šããšããããšæããŸãã
â»æ¬èšäºã¯AIã§ããçšåºŠã®èå¯ãå«ãæç« ãèªåã§äœæã§ããããšãå®èšŒãããšããããŒãžã§ããäžããææã¡ã§äœæãããããæ©ãã§ãã, åçã«æ¥œã«ãªãããšãããšè²¬ä»»ã¯æãŠãŸããâ»
0.2 å人æ å ±ã®åãæ±ãã«ã€ããŠ
äžå¿, ChatGPTã«ã¯private modeããããŸãããæ å ±æŒæŽ©ã®å±éºæ§ã¯åŠããªãã§ããç¹ã«å»åŠç³»ã®ã¬ããŒã (ç æŽèŠçŽ) ã¯æ£è æ å ±ãOpen AIã«æµåºãããŠããŸãå±éºãããã®ã§private modeã¯å¿ é ãšèããŸãã
â» 2025/5/6æŽæ°
æ³çãªèгç¹ãã, ãæ£è
ããåæãåŸãããå Žåãã§ãNGãšãªãåŸãŸã (âµæ£è
ãæ€åããå Žåã¯å人察å¿å°é£)ãå人ã®çæAI (LLM)ã§æ£è
æ
å ±ããã®ãŸãŸå
¥ããã®ã¯çµ¶å¯Ÿã«ãããæ¹ãããã§ãã
SNSã§ã¯ç§ãå«ã, æè¡çãªåŽé¢åãã, ç æŽèŠçŽãAIã§äœæåºæ¥ããã©ããã«ã€ããŠäžéšè°è«ã掻çºã§ãããããã«, æ¥æ¬å ç§åŠäŒ (å ç§å°æ»å»ç»é²è©äŸ¡ã·ã¹ãã (J-OSLER)ã«ãããçæAIå©çšã¬ã€ãã©ã€ã³) ã以äžã®ããã«å£°æãããã, å€ãã®å ç§å»åž«ãã䜿ã£ãŠãããã®ã§ã¯?ããšè§£éããŸãã (ãã¡ããç§ãå«ããŠ)ã

ãæ¬ã¬ã€ãã©ã€ã³ã®å 容ãååã«çè§£ããäžã§, çæAIãæŽ»çšããŠãã ããã
AIãå®å
šã«äœ¿çšããããã®æ¹æ³ãå·»æ«ã«è¿œèšäœæäžã§ãâ
1. æºå
1.1 å šäœã®æµã
â ç
æŽèŠçŽãã€ããããæ£è
æ
å ±ãèšèŒãããŠããçŽã«ã«ããé»åã«ã«ããããŸãã¯ããã¹ããã¡ã€ã«ã®åœ¢ã§æç« ãçšæããŸãã
â¡ è«æãChatGPTã«èªã¿èŸŒãŸãåŠç¿ããŠããããŸãã
⢠ããã³ãããçšããŠç
æŽèŠçŽãäœæããŸãã

åèæç®ã«é¢ããŠã¯å šèªåã§ChatGPTãæ€çŽ¢ããŠæã£ãŠããŠãããããã§ã¯ãªãã®ã§, èªåã§çšæããŠããæãæããŸãã
ããã£ãããã ããã
ãã£ãããšãèã ãæºåããŠãã ãããããšã¯CookDoãå ããã ãã§åéè (ãã€ã³ãŒããŠ) ãåºæ¥äžãããŸãã

ã¿ãããªã®ãã§ã
ãææ°ã§ãããè«æãã ãèªåã§æºåããŠãã ãããããšã¯ChatGPTããç
æŽèŠçŽããäœããŸãã®ã§ã



1.2 æ¶ç©ºã®é颿ãµããªãŒãæºå
ä»åã®èšäºã§ã¯ãæäººã¹ãã£ã«ç ãã®æ¶ç©ºçäŸã§é颿ãµããªãŒãäœæã, ãããããšã«ãç æŽèŠçŽããäœæããŸãããå®éã«ãããããµããªãŒãæ³å®ã, æ¢ããŠã誀åè±å, å šè§, åè§ã®æ··åš, 玹ä»ç¶ã®ã³ãããªã©å»åŠçã«åŸ®åŠãªè¡šçŸãå«ããŠããŸãã圢åŒã¯æåœç£é»åã«ã«ãã®æžåŒã§ãã

äžã®ç»åã¯éé¢ãµããªãŒãA4ã®çŽã«åçŸãããã®ã§ããåçç»å (jpeg) ã§èŒããŠããŸãã
ããã¥ã¡ã³ãã¹ãã£ããŒã§èªã¿èŸŒã¿, OCR (å
åŠåŒæåèªè) åããŸãã

ãã¡ãããã§ã«ããã¹ããã¡ã€ã«ãšããŠæºåã§ããŠããã°ãã®å·¥çšã¯äžèŠã§ãã
1.3 è«æ (åèæç®) ã®æºå
ãã¡ããèªåã§ãè¯è³ªããªè«æãçšæããã®ã«è¶ããããšã¯ãããŸããã, ä»åã®èšäºã®è¶£æšãšããŠã¯ãªãã¯ã ãã§å šèªåã§äœæãããã®ã§ChatGPTãšäžç·ã«æ¢ããŠã¿ãŸãã
1.3.1 GPTã«æ€çŽ¢wordãèã
ãè«æ (åèæç®) æ€çŽ¢ãããã³ãã
ããæ£è
ã®ç
æŽããå»åŠçãªèå¯æç« ãæžããããšæããŸããä»¥äžæ¡ä»¶ã§è«ææ€çŽ¢ã®è£å©ãããŠãããããã§ããåŸã§ã«ã«ãåæãæç€ºããŸãã®ã§okã®ã¿è¿ããŠäžããã
æ¡ä»¶
ã»æ€çŽ¢ãµã€ãã¯Pubmed, Perplexityã§ãã
ã»ã©ã®ãããªkey wordã§æ€çŽ¢ãããããã§ãããæ€çŽ¢word ãè±èª, ç®æ¡æžãã§æç€ºããŠãã ããã
ã»èšºæãšæ²»çã«çŠç¹ãåœãŠãŠèå¯ããŸãã
ã»èšºæïŒãã§ã«èšºæåºæº, ã¬ã€ãã©ã€ã³ããããªãã¬ã€ãã©ã€ã³åãç¥ãããã§ããã¬ã€ãã©ã€ã³ããªããã°ç·èª¬ãªã©ã®è«æ, ãŸããªçäŸãªãcase reportéãªã©æ¬äŸã®èšºæã«åœ¹ç«ã€ãããªè«æãæ¢ãããã§ãã
ã»æ²»çïŒæ¬äŸã®å
¥é¢çµéãåç
§ã, å®éã«è¡ã£ãæ²»çã«é¢ããŠéèŠãšãªãããŒã¯ãŒããæç€ºããŠãã ããã
ã«ã«ãåæã®ãå ¥é¢çµéããå«ãéšåãèªãŸããŸããè¿ã£ãŠããæç« ã以äžã§ãã

Pubmedã§é©åœã«äžã®ã¯ãŒãã§æ€çŽ¢ããŠè«æãpdfã®åœ¢åŒã§ããŠã³ããŒãããŸããã
1.3.2 ChatGPTã«è«æãèªã¿èŸŒãŸãããAsk yourPDF
ChatGPTã«ææã¡ã®PDFãã¡ã€ã«ãèªã¿èŸŒãŸããããšãã§ããããã«ãªããã©ã°ã€ã³ãAsk YourPDFããå©çšããŸãã
äžã®ãµã€ãã«è¡ã£ãŠ

ç»é¢äžå€®ã®ãšãªã¢ã«ææã¡ã®pdfãã¡ã€ã«ããã©ãã°ã¢ã³ãããããããŸãã

åºæ¥äžãã£ãIDãChatGPT (AskYourPDF) ã®ãã£ããæ¬ã«ã³ããããã°pdfãã¡ã€ã«ãèªèããŸãã以é, è«æã®èŠçŽãå 容ã«ã€ããŠæããŠããããå¿çšã¯å¹ åºãã§ãã

ä»åã®ç®çã¯, ChatGPTããç æŽèŠçŽããæžããããã«åŠç¿ããŠãããäºã§ãã
1.3.3 ChatGPTã«è«æãèªã¿èŸŒãŸãããAiPDF
Ask YourPDFã¯ç¡æçã®å Žå, çŸåš 1æ¥æ°ãã¡ã€ã«ããã¢ããããŒãã§ããŸããã®ã§ããã«äžéã«éããŸãã
AIPDFãåæ§ã®æ©èœãããäžå¿äœ¿ããŸãã粟床ã¯Ask YourPDFã®æ¹ã«è»é
ãäžãããŸãâŠ

ãã¡ã€ã«éžæã§ææã¡ã®pdfãã¢ããããŒãããŠããªã³ã¯IDããäœæããŸãã
1.3.4 Perplexityã§æ€çŽ¢ãã
AIæèŒã®è«ææ€çŽ¢ãµã€ãã§ãã

ããã»ã©ChatGPTãææ¡ããwordã§æ€çŽ¢ããŠã¿ãŸãã

ãã€ã¬ã¯ãã«èšºæåºæºãšãã®å
è«æã®ãªã³ã¯å
ã衚瀺ãããŠããŸãã
ãªã³ã¯å
ã«é£ãã§ã¿ãŸãã

䜿ããããªã®ã§äžå¿PDFã§ä¿åããŸããã
ä»ã«æºåããè«æïŒ
â Adult-Onset Stillâs Disease: Novel Biomarkers of Specific Subsets, Disease Activity, and Relapsing [Forms Int J Mol Sci . 2021]
â¡ Adult-onset Still's disease [Autoimmunity Reviews 13 (2014) 708-722.]
ä»åã¯è©Šäœãªã®ã§äžè¬çãªèšºæ, æ²»çã«ã€ããŠèšèŒãããŠããã°OKãšããŸããäžèšã®ç·èª¬ã2æ¬ãæºåããŸããã
å®é, èªåã§äœæãããšããã°æäººã¹ãã£ã«ç ã®ã¬ã€ãã©ã€ã³2017幎ã䜿ãã¹ãã§ãã, ä»åã¯å šãŠAIãäœæãšããããšã§ãAIãæšå¥šãããè«æã§äœã£ãŠã¿ãŸãã
1.4 泚æç¹, ã³ã
å
šäœçãªäœæã®ã³ãã§ãã
â å¿åŽ
åããã£ããæ¬ã§è³ªå, äœæãç¹°ãè¿ããš, éå»ã®ãã¡ãã®è³ªåå
容ãããçšåºŠèŠããŠãããŸãããã®å Žå, éãªããã³ããã§ã倧äžå€«ã§ãã, å¿ããŸãã®ã§, ãã®éœåºŠåãå
容ã®ããã³ãããæããããŠæãåºãããå¿
èŠããããŸãã
â¡ æ··ä¹±
èšå€§ãªéã®ããã¹ããäžåºŠã«åŠçããããšå®¹éè² è·ã§"æ··ä¹±"ããŠããŸããŸããäœæçã«1000æåçšåºŠã®ããã³ãããæãããããšç²ŸåºŠãèããäžãããŸããæ°çŸæåçšåºŠã«åå²ããŠäœæããŠãããŸãã
2. äœæ
â ãçŸç
æŽã â¡ ãå
¥é¢æçŸçã⢠ãå
¥é¢åŸçµéãšèå¯ã ⣠ç·åèå¯
†ãã®ä»ã
ã«åå²ã㊠1åãã€äœã£ãŠãããŸãã
2.1 ãçŸç æŽã
çŸç
æŽããã³ãã
ããããã«ã«ãåæãã以äžã®æ¡ä»¶ãããšã«ãçŸç
æŽããäœæããŠãã ãããåŸã§ã«ã«ãåæãæç€ºããŸãã®ã§okã®ã¿è¿ããŠäžããã
æ¡ä»¶
ã»200æåçšåºŠã§èšè¿°ããŠäžããã
ã»âã¯ã«ã«ãåæã®å
容ãåç
§ãæååã§çœ®æããŠãã ããã
ã»å»åŠçšèªã䜿çšãäŸãšããŠãåã®çã¿ã¯ãåœé çããæ¯èŠããã¯ãåŒåžèŠãã
ãµãã¶ãã®çã¿ã¯ãé¢ç¯çããšè¡šçŸããŸããç±ããŸãã¯ãè§£ç±é®çè¬ã
ã»å
¥é¢ã«è³ãçµç·¯ã«ã€ããŠèšèŒããæåŸã®è¡ã¯ã粟æ»å çã®ããâæâæ¥ã«âãžå
¥é¢ãšãªã£ããã
ã»åžžäœã§èšè¿°ïŒã§ããŸã調ã§ã¯ãªãïŒ
ã»éå»åœ¢ã§èšè¿°ã(ïœãã, ïœã§ãã£ã, ïœããã)
ã»æ£è
ã®èŠç¹ããèšè¿°, åºæ¬çã«ã¯ååæ
ã§ãïœããã ïœãåãããïœãšææããã
ã»èªãã, ã«ãŠ ãšããèªå¥ã䜿çšããªã
ã»â幎âæâæ¥ã§çµ±äž åã幎ã¯ç¹°ãè¿ããªãã2åç®ãããå幎âæâæ¥ã
ã»âç
é¢, âå»çã»ã³ã¿ãŒ, âã¯ãªããã¯ãªã©ç
é¢åãå®åã§èšè¿°ãããŠããããè¿å»ã, ãŸãã¯ãåå»ãã«å€æŽ
ã»é¢šéªè¬ãªã©è¬ååãå
·äœçã§ãªãã㰠颚éªè¬ (è©³çŽ°äžæ) ãšèšè¿°
ã»è¬åã¯äžè¬åãäŸïŒããã¢ãã¯ã¹âã»ãã«ãã³ãããã·ã«å¡©é
žå¡©
ç¥èªã¯å
šç§°ã«åæ§ç¯ãäŸïŒãªã°ãµã¯âãªãŒã°ã¡ã³ãã³/ãµã¯ã·ãªã³
ã»ããã®çµæããšãã衚çŸã¯äœ¿ããªã
ã»ãæ€æ»ã§ïœãèŠãããããšãã衚çŸã¯äœ¿ããªãããæ€æ»ã§âã®æèŠãææãããããããâãçããããããæ€æ»ã§âãçãããããªã©ãšãã
ã
ã»ç²Ÿæ»ãšæ²»çâ粟æ»å ç
ã»é«è¡å§âé«è¡å§ç, èç³âèç³ç
ã»ãæ¥ã«ãâãçªç¶ã, ãçŸãããâãåºçŸããã
ããã³ããã ããå ¥åããŠ, æ£è æ å ± (ã«ã«ãåæ) ã¯åŸããå ¥åããŸãããOKãã®ã¿è¿ããŠãããåŸ æ©ç¶æ ã«ããŸããÂ

æ£è æ å ±ã®çŸç æŽãå«ãŸããŠããç®æãã³ããããŸãã

åºæ¥äžãã£ãçŸç æŽã§ãããŸããŸãã®å®æåºŠã§ããããã³ããããŒã¯ã³ (å ¥åæã®æåæ°) ãå€ãããã埮åŠã«æå³ãäŒãã£ãŠããªãã£ãããåŒåŒµç±ãäžåç±ãšå€æãããããŠããŸãããç®ãã€ãããŸãã

æèè¬ã®ç¥èªãæ°ã«ãªãã®ã§ãç¥èªã¯äœ¿ããªãã§ãã ããããšããã³ããã®äžéšãã³ããããŠããäžåºŠåãæç€ºãããŸãã

äžåºŠã§ã¯å®ç§ãªæç« ãã§ããŸããã, ç°¡åãªä¿®æ£æç€ºãããã°å€§æµçè§£ããŠãããŸãã
2.2 ãå ¥é¢æçŸçã
ãå ¥é¢æçŸçããããé«åºŠãªåŠçãå¿ èŠãªã®ã§åç¬ã§åŠçããŸãã
å
¥é¢æçŸçããã³ãã
ããããã«ã«ãåæãã以äžã®æ¡ä»¶ãããšã«ãå
¥é¢æçŸçããäœæããŠãã ãããåŸã§ã«ã«ãåæãæç€ºããŸãã®ã§okã®ã¿è¿ããŠäžããã
æ¡ä»¶
ã»äŸããã®ãŸãŸåŒçšãããã®äžã§ç°åžžæèŠã倿ã远èšããã
ã»äŸã®æïŒãå
¥é¢æçŸçãèº«é· â cmïŒäœé â kgïŒäœæž© ââïŒèæ â /åïŒæŽïŒè¡å§ â/âmmHgïŒåŒåžæ° â /åïŒçŒçŒçµèã«è²§è¡ã¯ãªãïŒçŒççµèã«é»çžã¯ãªãïŒèžéšïŒèºé³ïŒå¿é³ã«ç°åžžã¯ãªãïŒè
¹éšïŒå¹³åŠïŒè»ã§å§çã¯ãªãïŒèã»èŸãè§Šç¥ããªãïŒåè¢ïŒäžè
¿æµ®è
«ãèªããªãïŒç®ç¹ãèªããªã.
ã»âã¯ã«ã«ãåæã®å
容ãåç
§ãæååã§çœ®æããŠãã ãããèšèŒããªããã°âã®ãŸãŸã
ã»å»åŠçšèªã䜿çšãäŸãšããŠãåã®çã¿ã¯ãåœé çããæ¯èŠããã¯ãåŒåžèŠãã
ãµãã¶ãã®çã¿ã¯ãé¢ç¯çããšè¡šçŸããŸãã
ã»åžžäœã§èšè¿°ïŒã§ããŸã調ã§ã¯ãªãïŒ
æèŠãããå Žåã¯ãïœãèªãããããªãå Žåã¯ãïœã¯ãªãããšèšè¿°ããäžæããšããèšèã¯äœ¿ããçç¥ããŠãã ãã
ã»ãã®ä»èº«äœæèŠã®å
·äœäŸ 以äžã®äŸãã«ã«ãåæã«æèšãããŠããã远èšããŠãã ããããªããã°çç¥ããŠãã ããã
ïŒJCS, GCS, ç³ååŸ, CVA婿çã®æç¡ãåºéã®æç¡ æè¡åµã®æç¡, è
žè åé³, PS, é¢ç¯ã®å§ç, è
«è¹,
ãªã³ãç¯ã®èç¥, ç¥çµåŠçæèŠ, æ§é³é害, å
±ååèŠ, 空éç¡èŠã®æç¡, MMT (äŸãã°äžè§ç4)ã, é·è°·å·åŒç¥èœè©äŸ¡ã¹ã±ãŒã«
ã»æ¹è¡, 空çœã¯äžèŠã§ããé£ç¶ããæååã§åºåããŠãã ããã
ç¹ã«åé¡ãªãåºåãããŸããã

2.3 ã䞻蚎ããæ€æ»é ç®ããªã©
é«åºŠãªåŠçãäžèŠãªæç« ã§ãã®ã§ç°¡åãªããã³ããã§ãåºåå¯èœã§ããäŸãã°æ€æ»é ç®ã®æŽåã§ã¯ä»¥äžã®ãããªããã³ããã§äœæã§ããããšãå€ãã§ãã
æ€æ»æèŠã以äžã®äŸã«ãªãã£ãŠé£ç¶ããæååã§åºåããŠãã ããã
äŸïŒèµ€è¡ç âäž/ÎŒL, Hb â g/dL,ã»ã»ã»ä»¥äžã®ãããªè©³çްããã³ããã䜿çšããã°GPT3.5ã§ãäœæã§ããŸã (3.5ã®å ŽåããŸã«ãšãã§ããªããã®ãäœæããŸããâŠ)ã
ãã®ä»ã䞻蚎ããæ€æ»é
ç®ããªã©ã®ããã³ãã
ããããã«ã«ãåæãã以äžã®æ¡ä»¶ãããšã«ã䞻蚎ããæ€æ»æèŠããªã©ãäœæããŠãã ãããåŸã§ã«ã«ãåæãæç€ºããŸãã®ã§okã®ã¿è¿ããŠäžããã
以äžã®åœ¢åŒã§åºåããŠãã ãããâã¯ã«ã«ãåæãã以äžã®æ¡ä»¶ã§èªå¥, æç« ãåç
§ããŠåæ§ç¯ãå
šãŠæååã«çœ®æããŠãã ãããã«ã«ãåæã«èšèŒããªããã°âã®ãŸãŸã§ã
åºå圢åŒïŒã䞻蚎ãâãæ¢åŸæŽãâã瀟äŒç掻æŽãâãå®¶ææŽãâãæ€æ»æèŠãâããããã¬ã ãªã¹ããïŒ#1.âã#2.âã#3.âïŒãéé¢æåŠæ¹ãâ
æ¡ä»¶ïŒå»åŠçšèªã«å€æããŠãã ãããäŸãšããŠãåã®çã¿ã¯ãåœé çããæ¯èŠããã¯ãåŒåžèŠãããµãã¶ãã®çã¿ã¯ãé¢ç¯çããšè¡šçŸããŸãã以äžã®æžåŒã«åŸã£ãŠèšè¿°ããŠãã ããïŒ
ãäž»èšŽãæ£è
ãå»çåŸäºè
ã«å¯ŸããŠèšŽããçç¶ã®äžã§æãéèŠãªãã®ãç
åã§ã¯ãªãæ£è
ã蚎ãã䞻芳çãªçç¶ãå
ã»ã©ã®çŸç
æŽããåç
§
ãæ¢åŸæŽãçŸåšæ²»çããŠããªãéå»ã®ç
æŽ, çŸæ£
ã瀟äŒç掻æŽãã¢ã¬ã«ã®ãŒæŽïŒ, å«ç
æŽïŒâæ¬Ãâ幎ãªã©ã§, 飲é
æŽ, è·æ¥
ãæ€æ»æèŠãäž»èŠãªæ€æ»æèŠãæãåºããŠä»¥äžã®åœ¢åŒã§æååãäœæããŠãã ãããæ€æ»æèŠä»¥å€ã®èšèŒã¯äžèŠã§ãã該åœããé
ç®ããªããã°â ã®ãŸãŸ
äŸïŒå°¿æèŠïŒã¿ã³ãã¯ïŒïŒïŒ, æœè¡ïŒïŒïŒ. è¡æ¶²æèŠïŒèµ€è¡ç âäž/ÎŒL, Hb â g/dL, Ht âïŒ
, çœè¡ç â/ÎŒLïŒNE âïŒ
, LY âïŒ
, MONO âïŒ
, EOS âïŒ
ïŒ, è¡å°æ¿ âäž/ÎŒL, PT âïŒ
, APTT âç§, è¡æŒ¿ãã£ããªãã²ã³ â mg/dL, è¡æž
FDP âÎŒg/mL. è¡æ¶²çååŠæèŠïŒTP â g/dL, Alb â g/dL, ãã§ãªãã³ â ng/mL, AST â U/L, ALT â U/L, LD â U/L, BUN â mg/dL, Cr â mg/dL. å
ç«è¡æž
åŠæèŠïŒCRP â mg/dL, ãªãŠããã€ãå åé°æ§, MPO-ANCA ïŒ â EU, PR3-ANCA ïŒâ EU, ææ žæäœé°æ§.ã
ããããã¬ã ãªã¹ãã#1.ã¯äž»ç
å #2, #3ã¯äž»ç
å, å
¥é¢åŸã®çµéãšé¢é£ããéèŠãªçŸæ£ãæ€æ»ç°åžž, çç¶ãªã©
ãéé¢åŠæ¹ãéé¢æåŠæ¹ãæœåºãäŸã®ããã«è¬åå çšéçšæ³ ã«ã³ãåè§ã¹ããŒã¹ã§æ¹è¡ãããã«æååãäœæããŠãã ãããè¬ååã¯ã¿ã±ããã³ã§ã¯ãªãã©ã³ãœãã©ãŸãŒã«ã®ããã«äžè¬åããã£ããããŒããåŠæ¹ã«å«ããŸããäŸïŒã©ã³ãœãã©ãŸãŒã« 15 mg 1Tãå1ãå€é£åŸ, ã¯ã«ãã¡ãªã³ã«ãªãŠã 1 mg 3.5T å1 å€é£åŸãæªãããšãããã¡ãã»ããããŸãã圢ã«ã¯ãªã£ãŠããŸããæ³šç®ãã¹ãã¯ã¯ã¬ã¢ããã³ããããšCre  O.35 mg/d lãããŒããã§ã¯ãªãããªãŒãã§äœããŸããã空æ°ãèªãã§0ããŒããã«çŽããŠãããŠãŸãã

ããã³ããæåæ°ãé·ããªããš"æ··ä¹±"ããŠç²ŸåºŠãèœã¡ãŸãã

ææãããšæ£ç¢ºã«ãã£ãŠãããŸããäžåºŠã§100%ã®çãã¯è¿ã£ãŠããŸããã
ééããããããšããã¡ããææããã ãã§èªå·±ä¿®æ£ããŠãããŸãã
2.4 ãå ¥é¢åŸçµéãšèå¯ã
äžè¬çãªæ§æãšããŠã蚺æããšãæ²»çãã®è©±ãäžå¿ã«å±éãå ¥é¢åŸçµéãèªãã°è¯ãããšæãããŸãã
2.4.1 ãå ¥é¢åŸçµéãšèå¯ãã蚺æpartã
ä»åçšæããæäººã¹ãã£ã«ç ã®ç·èª¬è«æã«ã¯, ã¹ãã£ã«ç 蚺æã§æåãªå±±å£åºæºãå«ãŸããŠããŸããã®ã§ãããå©çšããããšæããŸãããŸãã¯Ask YourPDFãçšããŠã蚺æãã«ã€ããŠGPTã«åŠç¿ããŠããããŸãã
Ask YourPDFã§èšºæãèŠçŽããããã³ãã
ããã«IDãã³ããããïŒ
Ask YourPDF ã§äžã®æç®ãåç
§ããŠäžããã
ãã®è«æã"ã¿ã€ãã«[éèªå 幎;å·»:ããŒãž]"(æ¹è¡ç©ºçœã¯äžèŠ é£ç¶ããæåå title[J Y;V:P])ã§è¡šç€ºããŠäžããã
蚺æïŒèšºæåºæºãèšèŒãããŠããã°æ¥æ¬èªã§è©³çްã«èšè¿°ããŠãã ãããäž»èŠåºæº, 坿¬¡åºæºãªã©ããªããã°, ã©ã®ããã«èšºæããã®ããå
·äœçã«ãŸãšããŠãã ããã蚺æåºæºãå¥ã®åŒçšæç®ã«ããã°, Referencesãåç
§ã, ãã®è«æã"ã¿ã€ãã«[éèªå 幎;å·»:ããŒãž]"(æ¹è¡ç©ºçœã¯äžèŠ é£ç¶ããæåå title[J Y;V:P])ã§è¡šç€ºããŠäžããã

ãã®è«æã«é¢ãã詳现ãåºåãããŸããã

ãããããšã«èšºæpartãäœã£ãŠããããŸãã
ãå
¥é¢åŸçµéãšèå¯ã蚺æpartäœæããã³ãã
ãããã以äžã®æ¡ä»¶ã§ãå
¥é¢åŸçµéãšèå¯ãã®èšºæpartãäœæããŠãã ãããã«ã«ãåæã¯åŸã»ã©æç€ºããŸããokã®ã¿è¿ããŠãã ããã
æ¡ä»¶
ã»ã§ããŸãå£èª¿ã§ã¯ãªããåžžæ
ã»ååæ
ã§ã¯ãªãèœåæ
ïŒçè
ç®ç·ïŒã§èšè¿°ãÃèããããããèãã
ã»ä»¥äžã®äŸãåèã«èšºæåºæº, 蚺æãèšè¿°ããè«æãåç
§ã, æåŸã®äžæã¯â以äžããââãšèšºæãããâã§çµãã
ã»å
ã»ã©ã®èšºæã«é¢ããè«æã蚺æåºæºã®èšèŒãããã°ãæ¬äŸã®ã«ã«ãåæãåç
§ã, åèŽé
ç®ã®ã¿ãèšè¿°ããŠäžãããäŸ1, ãPMRã®åé¡åºæºã®1. é¢ç¯ç, 2. 50æ³ä»¥äž, 3. ççåå¿é«å€ãèªã, 3é
ç®ãæºããããâ rãäŸ2.ãâã¬ã€ãã©ã€ã³ã®ââãæºããããâ rãâ
ã»èšºæåºæºã®èšèŒããªãå Žå, äŸ3. ãââã«é¢ãã詳现ãªèšºæåºæºã¯ãªãã, äžè¬çã«ââã§èšºæãè¡ãâ rã
ã»éå¥èšºæã3åæããŠãã ããã蚺æåºæºã®é€å€é
ç®ãããã°ãã®ãŸãŸåŒçšããäŸ4ããŸãéå¥èšºæãšããŠâ, â, â(3ã€)ãæããããã, âãªããšããåŠå®ãããã
äŸïŒå€çºæ§ç¡¬åçã§èŠããããããªè±åãé éšMRIã§ã®ç°åžžæèŠããªãããšããåŠå®ããã
ã»èšºæpartãªã®ã§èšºæä»¥å€, äŸãã°æ²»çã®èšè¿°ã¯äžèŠã§ãã
ã»äŸ1-4ã®åœ¢åŒã§200æåçšåºŠã§ãŸãšããŠãã ããã
ã»éç床, ç
æãªã©èšåºåé¡ããŠãã ãããäŸïŒèºçïŒADROPã¹ã³ã¢, CURB-65ã¹ã³ã¢, å¿äžå
šïŒNYHAæ©èœåé¡, ACC/AHAã¹ããŒãžã³ã°, æªæ§è
«çïŒTNMåé¡, ç³å°¿ç
ïŒHbA1c, ç³å°¿ç
ã®å䜵ç, COPDïŒGOLDåé¡, ã¢ã«ããã€ããŒç
ïŒè»œåºŠ, äžç床, é床, è
äžå
šïŒGFR, CKDã¹ããŒãž,ãå¿æ¿çްå CHADS2ã¹ã³ã¢
â rã¯åŒçšæç®ã§ããâã¿ã€ãã« [éèªå 幎ïŒå·»ïŒããŒãž]âã§çœ®ãæãâ rãšãã衚èšã¯äžèŠã§ããåŒçšæç®ã¯æã®æåŸã§ã¯ãªãéäžã«æ¿å
¥ããŠãã ããã
åæ§ã«ã«ã«ãåæã貌ãä»ããenter keyãæŒããŸãã

åå玹ä»ããæ¹æ³ãšæ¯ã¹ããš, å®æåºŠã®äœãã¯åŠããŸããã
ããã, ä»åã¯ãããã³ããããšãè«ææç€ºãã®ã¿ã§èªåäœæåºæ¥ãããšã«å€§ããªé²æ©ããããŸããã

ä»ã®åéã§ããã€ããã£ãŠã¿ãŸãããåçŸæ§ã¯é«ãã£ãã§ãã
2.4.2 ãå ¥é¢åŸçµéãšèå¯ããæ²»çpartã
ãã¡ããšããèå¯ã«é¢ããŠã¯ãç·åèå¯ãã§è¿°ã¹ãããšã«ã, ããã§ã¯çµéã®ã¿ãæ·¡ã
ãšèšè¿°ããŠããããŸãã
äŸã®åŠã以äžã®ããã³ãããæã¡èŸŒã¿, ã«ã«ãåæããå
¥é¢åŸçµéã®æ²»çãå«ãç®æãã³ããããŸãã
ãå
¥é¢åŸçµéãšèå¯ãæ²»çpartäœæããã³ãã
ãããã以äžã®æ¡ä»¶ã§ãå
¥é¢åŸçµéãšèå¯ãã®æ²»çpartãäœæããŠãã ãããã«ã«ãåæã¯åŸã»ã©æç€ºããŸããokã®ã¿è¿ããŠãã ããã
æ¡ä»¶
ã»ã§ããŸãå£èª¿ã§ã¯ãªããåžžæ
ã»ååæ
ã§ã¯ãªãèœåæ
ïŒçè
ç®ç·ïŒã§èšè¿°ãÃèããããããèãã
ã»æ¹è¡, 空çœã¯äžèŠ, é£ç¶ããæååã§è¡šç€ºããŠäžããã
ã»æ²»çéå§åŸã®çµéã説æããŠ, èšåºçç¶, æèŠã®æ¹å, éé¢ïŒæ¹åç¡ãæ»äº¡éé¢ïŒãŸã§ãèšè¿°ã
ã»æ²»ç以å€ã®è©±, äŸãã°èšºæã®èšè¿°ã¯äžèŠã§ãã
ã»å»åŠçšèªã«é¢ããŠãç¥èªãååºã®å Žåã¯ããã®å
šç§°ã«å€æããŠãã ããã2åç®ä»¥éã®åºçŸã§ã¯ç¥èªã䜿çšããŠãã ãããäŸ: GEMãåããŠäœ¿çšããéã«ã¯ãã²ã ã·ã¿ãã³(gemcitabine:以äžGEM)ããšè¡šèšãã2åç®ä»¥éã¯ãGEMããšèšè¿°ããŠãã ãããABVDãåããŠäœ¿çšããéã«ã¯ããããœã«ãã·ã³, ãã¬ãªãã€ã·ã³, ãã³ãã©ã¹ãã³, ãã«ã«ããžã³çæ³(以äžABVDçæ³)ããšè¡šèšãã2åç®ä»¥éã¯ãABVDçæ³ããšèšè¿°ããŠãã ãããè¬ååã¯äžè¬åã䜿çšããŠãã ãããæèè¬ã«é¢ããŠã¯sulbactam/ampicillin ïŒSBT/ABPCïŒ 3g 1æ¥ 3åã®ããã«äžè¬å (ç¥å) 1åæäžé 1æ¥äœåããåæ°ãªã©ã«ã«ãåæã«èšèŒããªããã°åç§°ã®ã¿ãã¹ããã€ãã¯ãã¬ãããŸãã³âmg/æ¥ã®ããã«äžæ¥éã
ã»äž»ç
åã«å¯Ÿããæ²»çãäž»ã«èšè¿°ãäž»ç
å以å€ã«ãå
¥é¢äžã«çºçããã€ãã³ãïŒé¢å
çºç±, åå äžæã®èžæ°Ž, æ²»çè¬å€ã«ããå¯äœçš, ã¢ã¬ã«ã®ãŒïŒã«å¯Ÿããæ²»ç, äºæ³ãããå¯äœçšã®äºé²ã«ã€ããŠãèšè¿°ããŠäžããã
äŸïŒãâæâæ¥ããâãéå§ãããã
äŸïŒãè¡æ çäºé²ã«å¯ŸããŠæç¶ãããªã³âunit/æ¥ãéå§ãããã
äŸïŒããŸã, ã¹ããã€ãæ§éªšç²é¬çäºé²ã®ããã¢ã¬ã³ããã³é
žãããªãŠã ãéå§ãããã
äŸïŒãAPTTãâãšå¹æãä¹ãããšå€æãâã«å¢éããããçºç±ãæç¶ã, åŒåžç¶æ
, ççåå¿ã®æ¹åãèªããâã«å€æŽããã
äŸïŒããã®åŸæ¹åãèªãâæ¥ã«éé¢ãšãããã

å 容ã¯ãšããã, æŽã£ãæç« ãåºåãããŸãããä¹±éãªæç« ã§ãèªåèªè, è§£éããŠãããŸãã

2.5 ãç·åèå¯ã
ç·åèå¯ã®æç« ã®æ§æãã¶ãã¯ãªãš2ãã¿ãŒã³ã«åé¡ããŠã¿ãŸããã
I. ãã©ã³ã¹åïŒæ²»çã®è©±ãã¡ã€ã³ã«ã, 蚺æ, æå°ãå°ãå«ããŸããå€ãã®ç
æŽèŠçŽããã®åã§ã¯ãªãããšæããŸãã
II. ç°å¢æŽå, å«çåïŒéé¢åŸã®ç°å¢æŽåãäž»ã«èšè¿°ããŸãã

2.5.1 ãç·åèå¯ããã©ã³ã¹å
é åºãšããŠã¯â è«ææç€ºââ¡ãç·åèå¯ãäžæžãäœæããã³ããââ¢ãå ¥é¢åŸçµéãšèå¯ãæç€ºââ£ æ ¡æ£ããã³ããããšãªããŸãã
â è«ææç€º


ããã§ã®ç®çã¯ãã¡ããè«æã®å 容ãç¥ãããããã§ã¯ãªã, ChatGPTã«åŠç¿ããŠãããããã§ãã

åŒãç¶ããã1æ¬ è«æãèªã¿èŸŒãŸããŸãã
â¡ãç·åèå¯ãäžæžãäœæããã³ãã

ã©ã®ãããªãç·åèå¯ããæžããã«ã€ããŠå€§ãŸããªå 容ãChatGPTã«æç€ºããããã®ããã³ããã§ããokã®ã¿è¿ã, ãã¡ããæç€ºãããŸã§åŸ æ©ããŠããããŸãã
â¢ãå
¥é¢åŸçµéãšèå¯ãæç€º
å
ã»ã©äœæãããå
¥é¢åŸçµéãšèå¯ããã³ããããŸãã

EnterãæŒã äžæžãã宿ããã®ãåŸ ã¡ãŸãã

ãå ¥é¢åŸçµéãšèå¯ããšçšæãããè«æãå 容ã«å¿ å®ãªäžæžãã宿ããŸãããå 容ãšããŠã¯åé¡ãããŸããããã®ãŸãŸã§ã¯ãç æŽèŠçŽãã®åœ¢åŒãšããŠã¯äžé©ã§ãã
â£ æ ¡æ£ããã³ãã
ãç·åèå¯ããèªåã§äœãã«ããããã¡ããå ¥åããããã³ããé (æç« é) ã¯èšå€§ã§ãããã®ãããæ··ä¹±ããå¿åŽãããããäžåºŠã§ã¯ç®çã®æç« ãçæãããŸããã以äžã®ããã³ããã§æŽããŸãã


æå°ã®ãã ããæããŠããŸã⊠è¯ããšããŸãïŒ
2.5.2 ç°å¢æŽå, å«çå
ä»åã®çäŸã¯ç°å¢æŽåã«ã€ããŠããŸãèšè¿°ããå¿ èŠããªãã£ãã®ã§å¥ã®çäŸã§äœã£ããã®ãäžã«æç€ºããŸãã

3. ãŸãšã, 課é¡, æ¹åç¹
ããšã®éé¢ãµããªãŒã¯ä¹±éãªæç« ã§ããã


è«æãšããã³ããã®ã¿ã§å 容ã¯ã¡ãã£ãšæªããã§ããäžå¿ãæŽã£ããã¬ããŒãã宿ããŸããã

ä»åã¯èªåäœæãç®æãããã®ã§ãã®ã§å 容äºã®æ¬¡ã§äœãããããåªå ããŸããã質ãåªå ãããšããæå³ã§ã¯, ããã³ããã®æ¹åã®äœå°ã¯ãããã§ãããããšæããŸãã
ChatGPT-4 ãçŸåšæ±ãããå¿åŽããæ··ä¹±ãã®åé¡ã解決ããã°, æäœã¯ããã«ç°¡ç¥åããå®å
šèªååããæ¥ããã£ãŠããã®ã§ã¯ãªãã§ããããã
4. ããã³ãã
4.0 è«ææ€çŽ¢
ãè«æ (åèæç®) æ€çŽ¢ãããã³ãã
ããæ£è
ã®ç
æŽããå»åŠçãªèå¯æç« ãæžããããšæããŸããä»¥äžæ¡ä»¶ã§è«ææ€çŽ¢ã®è£å©ãããŠãããããã§ããåŸã§ã«ã«ãåæãæç€ºããŸãã®ã§okã®ã¿è¿ããŠäžããã
æ¡ä»¶
ã»æ€çŽ¢ãµã€ãã¯Pubmed, Perplexityã§ãã
ã»ã©ã®ãããªkey wordã§æ€çŽ¢ãããããã§ãããæ€çŽ¢word ãè±èª, ç®æ¡æžãã§æç€ºããŠãã ããã
ã»èšºæãšæ²»çã«çŠç¹ãåœãŠãŠèå¯ããŸãã
ã»èšºæïŒãã§ã«èšºæåºæº, ã¬ã€ãã©ã€ã³ããããªãã¬ã€ãã©ã€ã³åãç¥ãããã§ããã¬ã€ãã©ã€ã³ããªããã°ç·èª¬ãªã©ã®è«æ, ãŸããªçäŸãªãcase reportéãªã©æ¬äŸã®èšºæã«åœ¹ç«ã€ãããªè«æãæ¢ãããã§ãã
ã»æ²»çïŒæ¬äŸã®å
¥é¢çµéãåç
§ã, å®éã«è¡ã£ãæ²»çã«é¢ããŠéèŠãšãªãããŒã¯ãŒããæç€ºããŠãã ããã4.1ãçŸç æŽã
çŸç
æŽããã³ãã
ããããã«ã«ãåæãã以äžã®æ¡ä»¶ãããšã«ãçŸç
æŽããäœæããŠãã ãããåŸã§ã«ã«ãåæãæç€ºããŸãã®ã§okã®ã¿è¿ããŠäžããã
æ¡ä»¶
ã»200æåçšåºŠã§èšè¿°ããŠäžããã
ã»âã¯ã«ã«ãåæã®å
容ãåç
§ãæååã§çœ®æããŠãã ããã
ã»å»åŠçšèªã䜿çšãäŸãšããŠãåã®çã¿ã¯ãåœé çããæ¯èŠããã¯ãåŒåžèŠãã
ãµãã¶ãã®çã¿ã¯ãé¢ç¯çããšè¡šçŸããŸããç±ããŸãã¯ãè§£ç±é®çè¬ã
ã»å
¥é¢ã«è³ãçµç·¯ã«ã€ããŠèšèŒããæåŸã®è¡ã¯ã粟æ»å çã®ããâæâæ¥ã«âãžå
¥é¢ãšãªã£ããã
ã»åžžäœã§èšè¿°ïŒã§ããŸã調ã§ã¯ãªãïŒ
ã»éå»åœ¢ã§èšè¿°ã(ïœãã, ïœã§ãã£ã, ïœããã)
ã»æ£è
ã®èŠç¹ããèšè¿°, åºæ¬çã«ã¯ååæ
ã§ãïœããã ïœãåãããïœãšææããã
ã»èªãã, ã«ãŠ ãšããèªå¥ã䜿çšããªã
ã»â幎âæâæ¥ã§çµ±äž åã幎ã¯ç¹°ãè¿ããªãã2åç®ãããå幎âæâæ¥ã
ã»âç
é¢, âå»çã»ã³ã¿ãŒ, âã¯ãªããã¯ãªã©ç
é¢åãå®åã§èšè¿°ãããŠããããè¿å»ã, ãŸãã¯ãåå»ãã«å€æŽ
ã»é¢šéªè¬ãªã©è¬ååãå
·äœçã§ãªãã㰠颚éªè¬ (è©³çŽ°äžæ) ãšèšè¿°
ã»è¬åã¯äžè¬åãäŸïŒããã¢ãã¯ã¹âã»ãã«ãã³ãããã·ã«å¡©é
žå¡©
ç¥èªã¯å
šç§°ã«åæ§ç¯ãäŸïŒãªã°ãµã¯âãªãŒã°ã¡ã³ãã³/ãµã¯ã·ãªã³
ã»ããã®çµæããšãã衚çŸã¯äœ¿ããªã
ã»ãæ€æ»ã§ïœãèŠãããããšãã衚çŸã¯äœ¿ããªãããæ€æ»ã§âã®æèŠãææãããããããâãçããããããæ€æ»ã§âãçãããããªã©ãšãã
ã
ã»ç²Ÿæ»ãšæ²»çâ粟æ»å ç
ã»é«è¡å§âé«è¡å§ç, èç³âèç³ç
ã»ãæ¥ã«ãâãçªç¶ã, ãçŸãããâãåºçŸããã4.2ãå ¥é¢æçŸçã
å
¥é¢æçŸçããã³ãã
ããããã«ã«ãåæãã以äžã®æ¡ä»¶ãããšã«ãå
¥é¢æçŸçããäœæããŠãã ãããåŸã§ã«ã«ãåæãæç€ºããŸãã®ã§okã®ã¿è¿ããŠäžããã
æ¡ä»¶
ã»äŸããã®ãŸãŸåŒçšãããã®äžã§ç°åžžæèŠã倿ã远èšããã
ã»äŸã®æïŒãå
¥é¢æçŸçãèº«é· â cmïŒäœé â kgïŒäœæž© ââïŒèæ â /åïŒæŽïŒè¡å§ â/âmmHgïŒåŒåžæ° â /åïŒçŒçŒçµèã«è²§è¡ã¯ãªãïŒçŒççµèã«é»çžã¯ãªãïŒèžéšïŒèºé³ïŒå¿é³ã«ç°åžžã¯ãªãïŒè
¹éšïŒå¹³åŠïŒè»ã§å§çã¯ãªãïŒèã»èŸãè§Šç¥ããªãïŒåè¢ïŒäžè
¿æµ®è
«ãèªããªãïŒç®ç¹ãèªããªã.
ã»âã¯ã«ã«ãåæã®å
容ãåç
§ãæååã§çœ®æããŠãã ãããèšèŒããªããã°âã®ãŸãŸã
ã»å»åŠçšèªã䜿çšãäŸãšããŠãåã®çã¿ã¯ãåœé çããæ¯èŠããã¯ãåŒåžèŠãã
ãµãã¶ãã®çã¿ã¯ãé¢ç¯çããšè¡šçŸããŸãã
ã»åžžäœã§èšè¿°ïŒã§ããŸã調ã§ã¯ãªãïŒ
æèŠãããå Žåã¯ãïœãèªãããããªãå Žåã¯ãïœã¯ãªãããšèšè¿°ããäžæããšããèšèã¯äœ¿ããçç¥ããŠãã ãã
ã»ãã®ä»èº«äœæèŠã®å
·äœäŸ 以äžã®äŸãã«ã«ãåæã«æèšãããŠããã远èšããŠãã ããããªããã°çç¥ããŠãã ããã
ïŒJCS, GCS, ç³ååŸ, CVA婿çã®æç¡ãåºéã®æç¡ æè¡åµã®æç¡, è
žè åé³, PS, é¢ç¯ã®å§ç, è
«è¹,
ãªã³ãç¯ã®èç¥, ç¥çµåŠçæèŠ, æ§é³é害, å
±ååèŠ, 空éç¡èŠã®æç¡, MMT (äŸãã°äžè§ç4)ã, é·è°·å·åŒç¥èœè©äŸ¡ã¹ã±ãŒã«
ã»æ¹è¡, 空çœã¯äžèŠã§ããé£ç¶ããæååã§åºåããŠãã ããã4.3ã䞻蚎ããæ€æ»é ç®ããªã©
ãã®ä»ã䞻蚎ããæ€æ»é
ç®ããªã©ã®ããã³ãã
ããããã«ã«ãåæãã以äžã®æ¡ä»¶ãããšã«ã䞻蚎ããæ€æ»æèŠããªã©ãäœæããŠãã ãããåŸã§ã«ã«ãåæãæç€ºããŸãã®ã§okã®ã¿è¿ããŠäžããã
以äžã®åœ¢åŒã§åºåããŠãã ãããâã¯ã«ã«ãåæãã以äžã®æ¡ä»¶ã§èªå¥, æç« ãåç
§ããŠåæ§ç¯ãå
šãŠæååã«çœ®æããŠãã ãããã«ã«ãåæã«èšèŒããªããã°âã®ãŸãŸã§ã
åºå圢åŒïŒã䞻蚎ãâãæ¢åŸæŽãâã瀟äŒç掻æŽãâãå®¶ææŽãâãæ€æ»æèŠãâããããã¬ã ãªã¹ããïŒ#1.âã#2.âã#3.âïŒãéé¢æåŠæ¹ãâ
æ¡ä»¶ïŒå»åŠçšèªã«å€æããŠãã ãããäŸãšããŠãåã®çã¿ã¯ãåœé çããæ¯èŠããã¯ãåŒåžèŠãããµãã¶ãã®çã¿ã¯ãé¢ç¯çããšè¡šçŸããŸãã以äžã®æžåŒã«åŸã£ãŠèšè¿°ããŠãã ããïŒ
ãäž»èšŽãæ£è
ãå»çåŸäºè
ã«å¯ŸããŠèšŽããçç¶ã®äžã§æãéèŠãªãã®ãç
åã§ã¯ãªãæ£è
ã蚎ãã䞻芳çãªçç¶ãå
ã»ã©ã®çŸç
æŽããåç
§
ãæ¢åŸæŽãçŸåšæ²»çããŠããªãéå»ã®ç
æŽ, çŸæ£
ã瀟äŒç掻æŽãã¢ã¬ã«ã®ãŒæŽïŒ, å«ç
æŽïŒâæ¬Ãâ幎ãªã©ã§, 飲é
æŽ, è·æ¥
ãæ€æ»æèŠãäž»èŠãªæ€æ»æèŠãæãåºããŠä»¥äžã®åœ¢åŒã§æååãäœæããŠãã ãããæ€æ»æèŠä»¥å€ã®èšèŒã¯äžèŠã§ãã該åœããé
ç®ããªããã°â ã®ãŸãŸ
äŸïŒå°¿æèŠïŒã¿ã³ãã¯ïŒïŒïŒ, æœè¡ïŒïŒïŒ. è¡æ¶²æèŠïŒèµ€è¡ç âäž/ÎŒL, Hb â g/dL, Ht âïŒ
, çœè¡ç â/ÎŒLïŒNE âïŒ
, LY âïŒ
, MONO âïŒ
, EOS âïŒ
ïŒ, è¡å°æ¿ âäž/ÎŒL, PT âïŒ
, APTT âç§, è¡æŒ¿ãã£ããªãã²ã³ â mg/dL, è¡æž
FDP âÎŒg/mL. è¡æ¶²çååŠæèŠïŒTP â g/dL, Alb â g/dL, ãã§ãªãã³ â ng/mL, AST â U/L, ALT â U/L, LD â U/L, BUN â mg/dL, Cr â mg/dL. å
ç«è¡æž
åŠæèŠïŒCRP â mg/dL, ãªãŠããã€ãå åé°æ§, MPO-ANCA ïŒ â EU, PR3-ANCA ïŒâ EU, ææ žæäœé°æ§.ã
ããããã¬ã ãªã¹ãã#1.ã¯äž»ç
å #2, #3ã¯äž»ç
å, å
¥é¢åŸã®çµéãšé¢é£ããéèŠãªçŸæ£ãæ€æ»ç°åžž, çç¶ãªã©
ãéé¢åŠæ¹ãéé¢æåŠæ¹ãæœåºãäŸã®ããã«è¬åå çšéçšæ³ ã«ã³ãåè§ã¹ããŒã¹ã§æ¹è¡ãããã«æååãäœæããŠãã ãããè¬ååã¯ã¿ã±ããã³ã§ã¯ãªãã©ã³ãœãã©ãŸãŒã«ã®ããã«äžè¬åããã£ããããŒããåŠæ¹ã«å«ããŸããäŸïŒã©ã³ãœãã©ãŸãŒã« 15 mg 1Tãå1ãå€é£åŸ, ã¯ã«ãã¡ãªã³ã«ãªãŠã 1 mg 3.5T å1 å€é£åŸã4.4 ãå ¥é¢åŸçµéãšèå¯ã
è«æåŠç¿
Ask YourPDFã§èšºæãèŠçŽããããã³ãã
ããã«IDãã³ããããïŒ
Ask YourPDF ã§äžã®æç®ãåç
§ããŠäžããã
ãã®è«æã" [éèªå 幎;å·»:ããŒãž]"(æ¹è¡ç©ºçœã¯äžèŠ é£ç¶ããæåå [J Y;V:P])ã§è¡šç€ºããŠäžããã
蚺æïŒèšºæåºæºãèšèŒãããŠããã°æ¥æ¬èªã§è©³çްã«èšè¿°ããŠãã ãããäž»èŠåºæº, 坿¬¡åºæºãªã©ããªããã°, ã©ã®ããã«èšºæããã®ããå
·äœçã«ãŸãšããŠãã ããã蚺æåºæºãå¥ã®åŒçšæç®ã«ããã°, Referencesãåç
§ã, ãã®è«æã"ã¿ã€ãã«[éèªå 幎;å·»:ããŒãž]"(æ¹è¡ç©ºçœã¯äžèŠ é£ç¶ããæåå title[J Y;V:P])ã§è¡šç€ºããŠäžããã
蚺æpart
ãå
¥é¢åŸçµéãšèå¯ã蚺æpartäœæããã³ãã
ãããã以äžã®æ¡ä»¶ã§ãå
¥é¢åŸçµéãšèå¯ãã®èšºæpartãäœæããŠãã ãããã«ã«ãåæã¯åŸã»ã©æç€ºããŸããokã®ã¿è¿ããŠãã ããã
æ¡ä»¶
ã»ã§ããŸãå£èª¿ã§ã¯ãªããåžžæ
ã»ååæ
ã§ã¯ãªãèœåæ
ïŒçè
ç®ç·ïŒã§èšè¿°ãÃèããããããèãã
ã»ä»¥äžã®äŸãåèã«èšºæåºæº, 蚺æãèšè¿°ããè«æãåç
§ã, æåŸã®äžæã¯â以äžããââãšèšºæãããâã§çµãã
ã»å
ã»ã©ã®èšºæã«é¢ããè«æã蚺æåºæºã®èšèŒãããã°ãæ¬äŸã®ã«ã«ãåæãåç
§ã, åèŽé
ç®ã®ã¿ãèšè¿°ããŠäžãããäŸ1, ãPMRã®åé¡åºæºã®1. é¢ç¯ç, 2. 50æ³ä»¥äž, 3. ççåå¿é«å€ãèªã, 3é
ç®ãæºããããâ rãäŸ2.ãâã¬ã€ãã©ã€ã³ã®ââãæºããããâ rãâ
ã»èšºæåºæºã®èšèŒããªãå Žå, äŸ3. ãââã«é¢ãã詳现ãªèšºæåºæºã¯ãªãã, äžè¬çã«ââã§èšºæãè¡ãâ rã
ã»éå¥èšºæã3åæããŠãã ããã蚺æåºæºã®é€å€é
ç®ãããã°ãã®ãŸãŸåŒçšããäŸ4ããŸãéå¥èšºæãšããŠâ, â, â(3ã€)ãæããããã, âãªããšããåŠå®ãããã
äŸïŒå€çºæ§ç¡¬åçã§èŠããããããªè±åãé éšMRIã§ã®ç°åžžæèŠããªãããšããåŠå®ããã
ã»èšºæpartãªã®ã§èšºæä»¥å€, äŸãã°æ²»çã®èšè¿°ã¯äžèŠã§ãã
ã»äŸ1-4ã®åœ¢åŒã§200æåçšåºŠã§ãŸãšããŠãã ããã
ã»éç床, ç
æãªã©èšåºåé¡ããŠãã ãããäŸïŒèºçïŒADROPã¹ã³ã¢, CURB-65ã¹ã³ã¢, å¿äžå
šïŒNYHAæ©èœåé¡, ACC/AHAã¹ããŒãžã³ã°, æªæ§è
«çïŒTNMåé¡, ç³å°¿ç
ïŒHbA1c, ç³å°¿ç
ã®å䜵ç, COPDïŒGOLDåé¡, ã¢ã«ããã€ããŒç
ïŒè»œåºŠ, äžç床, é床, è
äžå
šïŒGFR, CKDã¹ããŒãž,ãå¿æ¿çްå CHADS2ã¹ã³ã¢
â rã¯åŒçšæç®ã§ããâã¿ã€ãã« [éèªå 幎ïŒå·»ïŒããŒãž]âã§çœ®ãæãâ rãšãã衚èšã¯äžèŠã§ããåŒçšæç®ã¯æã®æåŸã§ã¯ãªãéäžã«æ¿å
¥ããŠãã ããã
æ²»çpart
ãå
¥é¢åŸçµéãšèå¯ãæ²»çpartäœæããã³ãã
ãããã以äžã®æ¡ä»¶ã§ãå
¥é¢åŸçµéãšèå¯ãã®æ²»çpartãäœæããŠãã ãããã«ã«ãåæã¯åŸã»ã©æç€ºããŸããokã®ã¿è¿ããŠãã ããã
æ¡ä»¶
ã»ã§ããŸãå£èª¿ã§ã¯ãªããåžžæ
ã»ååæ
ã§ã¯ãªãèœåæ
ïŒçè
ç®ç·ïŒã§èšè¿°ãÃèããããããèãã
ã»æ¹è¡, 空çœã¯äžèŠ, é£ç¶ããæååã§è¡šç€ºããŠäžããã
ã»æ²»çéå§åŸã®çµéã説æããŠ, èšåºçç¶, æèŠã®æ¹å, éé¢ïŒæ¹åç¡ãæ»äº¡éé¢ïŒãŸã§ãèšè¿°ã
ã»æ²»ç以å€ã®è©±, äŸãã°èšºæã®èšè¿°ã¯äžèŠã§ãã
ã»å»åŠçšèªã«é¢ããŠãç¥èªãååºã®å Žåã¯ããã®å
šç§°ã«å€æããŠãã ããã2åç®ä»¥éã®åºçŸã§ã¯ç¥èªã䜿çšããŠãã ãããäŸ: GEMãåããŠäœ¿çšããéã«ã¯ãã²ã ã·ã¿ãã³(gemcitabine:以äžGEM)ããšè¡šèšãã2åç®ä»¥éã¯ãGEMããšèšè¿°ããŠãã ãããABVDãåããŠäœ¿çšããéã«ã¯ããããœã«ãã·ã³, ãã¬ãªãã€ã·ã³, ãã³ãã©ã¹ãã³, ãã«ã«ããžã³çæ³(以äžABVDçæ³)ããšè¡šèšãã2åç®ä»¥éã¯ãABVDçæ³ããšèšè¿°ããŠãã ãããè¬ååã¯äžè¬åã䜿çšããŠãã ãããæèè¬ã«é¢ããŠã¯sulbactam/ampicillin ïŒSBT/ABPCïŒ 3g 1æ¥ 3åã®ããã«äžè¬å (ç¥å) 1åæäžé 1æ¥äœåããåæ°ãªã©ã«ã«ãåæã«èšèŒããªããã°åç§°ã®ã¿ãã¹ããã€ãã¯ãã¬ãããŸãã³âmg/æ¥ã®ããã«äžæ¥éã
ã»äž»ç
åã«å¯Ÿããæ²»çãäž»ã«èšè¿°ãäž»ç
å以å€ã«ãå
¥é¢äžã«çºçããã€ãã³ãïŒé¢å
çºç±, åå äžæã®èžæ°Ž, æ²»çè¬å€ã«ããå¯äœçš, ã¢ã¬ã«ã®ãŒïŒã«å¯Ÿããæ²»ç, äºæ³ãããå¯äœçšã®äºé²ã«ã€ããŠãèšè¿°ããŠäžããã
äŸïŒãâæâæ¥ããâãéå§ãããã
äŸïŒãè¡æ çäºé²ã«å¯ŸããŠæç¶ãããªã³âunit/æ¥ãéå§ãããã
äŸïŒããŸã, ã¹ããã€ãæ§éªšç²é¬çäºé²ã®ããã¢ã¬ã³ããã³é
žãããªãŠã ãéå§ãããã
äŸïŒãAPTTãâãšå¹æãä¹ãããšå€æãâã«å¢éããããçºç±ãæç¶ã, åŒåžç¶æ
, ççåå¿ã®æ¹åãèªããâã«å€æŽããã
äŸïŒããã®åŸæ¹åãèªãâæ¥ã«éé¢ãšãããã
4.5 ãç·åèå¯ã
è«æåŠç¿
ãç·åèå¯ãæ²»ç:è«æåŠç¿ããã«IDãã³ããããïŒ
Ask YourPDF ã§äžã®æç®ãåç
§ããŠäžããããã®è«æã"[éèªå 幎;å·»:ããŒãž]"(æ¹è¡ç©ºçœã¯
äžèŠ é£ç¶ããæåå [J Y;V:P])ã§è¡šç€ºããŠäžããã
æ²»çã«é¢ããŠéç床, ã¹ã³ã¢ããšã«æ²»çæ³ãç°ãªãã°ãããããã®æ²»çæ³ã«ã€ããŠ,
䜿çšããè¬å€, çšé, æéãªã©å
·äœçã«è©³çްã«èšè¿°ããŠãã ãããå
šãŠæ¥æ¬èªã§èšè¿°ããŠãã ãããäžæžãäœæ
ãç·åèå¯ãäžæžãäœæããã³ãã
ãå
¥é¢åŸçµéãšèå¯ããã以äžã®æ¡ä»¶ã§ãç·åèå¯ãã®ãäžæžãããäœæããŠãã ãããçè
ã®èšåºçãªæŽå¯ãšåæãå人çãªè©äŸ¡ãè§£éã«éç¹ã眮ããŠããŸããæ²»çã«ã€ããŠéç¹çã«è¿°ã¹ãŸãããå
¥é¢åŸçµéãšèå¯ãã¯çšæç€ºããŸããokã®ã¿è¿ããŠãã ããã
â 蚺æ:ãã®çäŸã®ç¢ºå®èšºæåãè¿°ã¹ãŸããç°¡ç¥ã«è¿°ã¹ãŸã
äŸïŒãæ¬äŸã¯â ãšèšºæãâ ãè¡ã£ãäŸã§ãããã
â¡ æ²»ç: ãã®çäŸã§è¡ãããå
·äœçãªæ²»çæ³ïŒè¬å€å, ã¬ãžã¡ã³ãè¿°ã¹ãŸãçšéçšæ³ã¯äžèŠïŒã«ã€ããŠèª¬æããŸããçŸåšã®ã¬ã€ãã©ã€ã³ãä»ã®ç ç©¶ã§æšå¥šãããŠããæ²»çæ³ãšããã®çäŸã§è¡ãããæ²»çæ³ãæ¯èŒã, å¿
èŠæ§ãåŠ¥åœæ§ãè©äŸ¡ããŸãããŸã, å®éè¡ã£ãŠããªããå¿
èŠãšèããæ²»çãªã©ä»ã®ç ç©¶ã®ç޹ä»ãèªåã®èããšããŠèšè¿°ããŸããå
ã»ã©Ask YourPDFã§æç€ºããåèæç®ã«èšè¿°ãããŠããæ²»çæ³ã¯ã©ã®ãããªç¶æ³ã§äœ¿çšã, æ¬äŸãšæ¯èŒããŠå°å
¥åºæºãèå¯ããŸããæäžã«è€æ°ã®åŒçšæç®2-3åèšèŒããŠäžããã
⢠æå°ïŒãå
¥é¢åŸçµéãšèå¯ãã§èšåãããŠããªããŠã以äžã®å
å®¹ã§æ£è
æå°ãããšããããšã«ãããæ£è
ãæ¹åãã¹ãçæŽ»ç¿æ
£ã«ã€ããŠèå¯ããŸããåçºãé²ãããã®å
·äœçãªæå°ãå§åãæäŸããŸãã䜿çšè¬å€ã«å¯Ÿããæå°ã®èšè¿°ãäŸãã°ã¹ããã€ã䜿çšã«ããåºçŸããå¯äœçšå¯Ÿçãªã©ã1, 2æã§çãã«èšè¿°ããŸãã
æ ¡æ£
ãç·åèå¯ãæ ¡æ£ããã³ãã
ãç·åèå¯ãã®ãäžæžããã以äžã®æ¡ä»¶ã§æ ¡æ£ããç·åèå¯ãã宿ãããŠãã ããã
æ¡ä»¶ïŒ
ã»ã§ããŸãå£èª¿ã§ã¯ãªããåžžæ
ãïœã§ããã
ã»ååæ
ã§ã¯ãªãèœåæ
ïŒçè
ç®ç·ïŒã§èšè¿°ãÃèãããã, æãããããèãã
ã»æ¹è¡, 空çœã¯äžèŠ, ãŸããâ 蚺æããªã©ã®titleã¯äžèŠã§é£ç¶ããæååã§è¡šç€ºããŠäžããã
ã»â ã¯å
šãŠæååã§çœ®æããŠãã ããã
ã»â rã¯åŒçšæç®ã§ããâ [éèªå 幎ïŒå·»ïŒããŒãž]âã§çœ®ãæãâ rãšãã衚èšã¯äžèŠã§ããåŒçšæç®ã¯æã®æåŸã§ã¯ãªãéäžã«æ¿å
¥ããŠãã ããã
äŸïŒãæ¬äŸã¯â ãšèšºæãâ ãè¡ã£ãäŸã§ãããã
äŸïŒãâ rã§ã¯â ã«å¯ŸããŠâ ãæšå¥šãããŠãããã
äŸïŒãâ ã§ã¯â ããã°ãã°åé¡ãšãªãããâ ãè¡ãâ rãã
äŸïŒãæ¬äŸã«ã¯è¡ã£ãŠããªããâ ãšããå ±åãããâ rãã
äŸïŒãâ ã¯â ã«ããåçããããšãããããŠããâ ãæå°ãããã
äŸïŒãâ ã¯äœ¿çšã«ããâ ãåºçŸãããªã¹ã¯ãããããâ ãã
ç°å¢æŽå, å«çå
ãç·åèå¯ãç°å¢æŽå, å«çå äœæããã³ãã
å
ã»ã©ã®ãå
¥é¢åŸçµéãšèå¯ããã以äžã®æ¡ä»¶ã§ãç·åèå¯ããäœæããŠãã ããã
éé¢åŸã®ç°å¢æŽåãéèŠãšãªã£ãçäŸã«é¢ããŠã¯â ã®å
容ãéç¹çã«, å«ççèå¯ãéèŠã®å Žåã¯â¡ãéç¹çã«è¿°ã¹ãŠãã ããã䞻治å»ãšããŠçŸæ£ã®æ²»çã ãã§ãªã, ãªãŒããŒã·ãããçºæ®ãéé¢åŸã®ç°å¢æŽåãæ§ç¯ãã, çµæ«æã®å»çãã«ç·åçã«èå¯ããããšã«éç¹ã眮ããŠããŸãã
æ¡ä»¶ïŒ
ã»ã§ããŸãå£èª¿ã§ã¯ãªããåžžæ
ã»ååæ
ã§ã¯ãªãèœåæ
ïŒçè
ç®ç·ïŒã§èšè¿°ãÃèãããã, æãããããèãã
ã»æ¹è¡, 空çœã¯äžèŠã§é£ç¶ããæååã§è¡šç€ºããŠäžããã
â 瀟äŒçèæ¯ãšçæŽ»ç¶æ³ãªã©æ£è
ã®èæ¯ãææ¡ããŸããæ£è
ã®ã©ã€ãã¹ããŒãžãå®¶æã®æ§æãå®¶äºãåŠåš ãåè²ãŠãè·æ¥ãªã©ãç¹ã«é«éœ¢è
ã®å Žåã«ã¯ãèªç«ç掻ã®å¯èœæ§ãåå±
ä»è·è
ã®æç¡ãªã©ã®å
·äœçãªç¶æ³ãè©³çŽ°ã«ææ¡ããŸããæ©æããå°åå
æ¬ã±ã¢ã·ã¹ãã ãªã©ã®å
¬çæ©é¢ãç£æ¥å»ãå€è·çš®éã®é£æºãã¯ãããŸããä»è·ã蚪å蚺çããªãããªããŒã·ã§ã³ãªã©ãå«ãå
šäœçãªã±ã¢ãã©ã³ãçå®ããŸãããŸããå°åã®ãªãœãŒã¹ïŒãã€ãµãŒãã¹ãå°åçŠç¥ãµãŒãã¹ãé«éœ¢è
åãã®ç€ŸäŒæŽ»åçïŒãæäŸã掻çšããŸãã
â¡ æ£è
ã®èªå·±æ±ºå®æš©ãå°éããèŠç¹ããå
šäººçãªèå¯ãè¡ããŸããæ£è
ã®å¿ççã瀟äŒçãæåçãªç¶æ³ã«ã€ããŠã®èå¯ãæ·±ããŸããæ²»çæäŸã«ãããå
¬å¹³æ§ã«ã€ããŠã®æ·±ãèå¯ãæäŸããŸããçµæ«æã»ç·©åå»çã®èå¯: çµæ«æã®æ²»çãç·©åå»çã®èŠç¹ããã®æ·±ãèå¯ãè¡ããŸãã
5. æ£è æ å ±ä¿è·ã®èгç¹ããçæAIãå®å šã«äœ¿çšããããã« â»2025/5/6 远èš
â äœæäžã§ãâ
å ç§å°æ»å»ç»é²è©äŸ¡ã·ã¹ãã (J-OSLER)ã«ãããçæAIå©çšã¬ã€ãã©ã€ã³
ãæ¬ã¬ã€ãã©ã€ã³ã¯ãJ-OSLERã«ãããŠãå ç§ã®å°æ»å»ãChatGPTãªã©ã®çæAIãå©çšããéã«æ³šæãã¹ãäºé ãå®ãããã®ã§ãã
ãçæAIã¯æ¥åå¹çã®æ¹åãå»åŠã®ç¥èãçäŸã«é¢ããæ å ±ã®è£å®ã«æŽ»çšããããšãã§ããŸãããå¿çã«çšããåŠç¿ããŒã¿ã«ã¯ãã€ã¢ã¹ã誀ã£ãæ å ±ãå«ãŸããå¯èœæ§ããããæã«ã¯åã£ãæ å ±ã誀ã£ãæ å ±ãæäŸããããšãããããã驿£ãªå©çšãè¡ãå¿ èŠããããŸããJ-OSLERã«ç»é²ããææžã®äœæã«çæAIãå©çšããéã«ã¯æ¬ã¬ã€ãã©ã€ã³ã®å 容ãååã«çè§£ããäžã§ãçæAIãæŽ»çšããŠãã ããããªããæ¬ã¬ã€ãã©ã€ã³ã¯çæAIã®äœ¿çšãæšå¥šãããã®ã§ã¯ãããŸããã
ãçæAIå©çšã«ãããéµå®äºé ã
1. å ¥åå 容ãåŠç¿å 容ã«åæ ããªãèšå®ãããäžã§å©çšããããšã
2. æ£è ã®å人è奿 å ±ãå ¥åããªãããšïŒIDãååãäœæãçå¹Žææ¥ãªã©ïŒã
3. å°æ»å»ã®çµéšçäŸã®åçš¿ã®äžã«ãå·çéçšã«ãããçæAIã®äœ¿çšçšéã«ã€ããŠã®é瀺ãè¡ãããšãçæAIã®äœ¿çšãè¡ãããããšåã³ãã®åœ¹å²ãæç¢ºã«èª¬æããããšã§ãè©äŸ¡è ãæ å ±ã®ä¿¡é Œæ§ãæ£ããè©äŸ¡ããããšãã§ããããã«ãªããŸãã
4. èªå·±çå¯ã»èå¯ã®èšèŒã«ãããŠã¯ãçæAIã®åºåããã®ãŸãŸè€åããŠå©çšãããå°æ»å»èªèº«ã®èšèã§èšèŒããããšã
ãçæç©ã®å©çšã«éããæ³šæäºé ã
1. çäŸã«å¯Ÿããèå¯ã®æ å ±è£å®ã«ãããçæAIã®åºåçµæã¯åèã«ãªãå ŽåããããŸãããçæAIã¯ãããŸã§ãè£å®çãªããŒã«ã§ããçæAIã®åºåãåèã«ããå Žåããæ å ±ãéµåã¿ã«ããã«æ£ç¢ºæ§ãé©åæ§ã倿ããå°æ»å»ã®ç¥èãšåŠä¿®ãšçµéšãããšã«æçµã¬ããŒããäœæããããšã
2. çæAIãçäŸèŠçŽã«çšããå ŽåãçæAIã®åºåã¯æã«éèŠãªæ å ±ãèŠç¹ãæ¬ èœããå ŽåããããŸãããŸããçµæã¯æ©æ¢°çæããããã®ã§ãããããæäœãå°éçšèªã®èª¿æŽãå¿ èŠã«ãªãå ŽåããããŸããçäŸèŠçŽã«çæAIãçšããéã¯ãçæAIã®åºåã«ããããå°éçšèªã®æ£ç¢ºæ§ãççŸç¹ãªã©ç¢ºèªããäžã§ãå·çè ã責任ããã£ãŠã¬ããŒããäœæããããšã
3. çæAIã¯ãé¢é£ããæç®ãç¹å®ããããã®ã¢ã·ã¹ã¿ã³ããšããŠäœ¿çšããããšãã§ããŸãããæšå¥šãããæç®ã«ãã€ã¢ã¹ããããããšããããŸãã®ã§ãåèã®å 容ã確èªããäžã§å·çè ã責任ãæã£ãŠåŒçšã®æ¯éã倿ããããšã
什å6幎11æ9æ¥